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Primary prevention of sudden cardiac death using
implantable cardioverter defibrillators
More patients need to be screened and treated
The National Institute for Clinical Excellence(NICE) has recommended that implantablecardioverter defibrillators should be routinely
considered for patients who have survived ventricular
fibrillation or ventricular tachycardia with haemo›
dynamic compromise for secondary prevention of
arrhythmic death. It also recommends it in certain
patients who have not yet had a serious arrhythmic
event but who are at high risk of sudden cardiac death
as primary prevention. This second group comprises
mainly patients who have survived a myocardial infarc›
tion. Only a tiny minority of these patients is currently
being investigated and treated with implantable
defibrillators.
After an infarction, impaired ventricular function
with an ejection fraction of 35% or less, non›sustained
ventricular tachycardia (three beats or more) on ambu›
latory 24 hour monitoring, and inducible ventricular
tachycardia at electrophysiological testing identify a
subgroup of patients at high risk of sudden death.
Paradoxically, antiarrhythmic drugs increase the risk of
death and should be avoided in patients with
significantly impaired ventricular function.1 At best,
amiodarone decreases the risk of sudden death slightly
but does not affect overall mortality, with a risk reduc›
tion of 13%›15%.2
Two prospective randomised controlled trials of
preventive strategies have shown the benefit of the
implantable cardioverter defibrillator in this high risk
group. The multicentre automatic defibrillator trial, or
MADIT, compared the implantable cardioverter
defibrillator with best medical treatment, which
included amiodarone in 74% of the control group.3 It
was a relatively small study, justified by its sequential
trial design. The multicentre unsustained tachycardia
trial, or MUSTT, compared an electrophysiologically
guided strategy with no antiarrhythmic therapy.4 The
strategy involved serial drug testing—antiarrhythmic
drugs were given, and the electrophysiology study
repeated to determine if ventricular tachycardia could
still be induced. Suppression of induction of ventricu›
lar tachycardia was deemed a success. If not,
antiarrhythmic drugs were withdrawn and an implant›
able cardioverter defibrillator implanted. Although this
was not a trial of the implantable cardioverter defibril›
lator itself, benefit was seen only in those patients
treated with defibrillators.
Both these trials have shown that implantable
cardioverter defibrillators confer a relative risk
reduction of 54%›60% in all›cause mortality. Using this
evidence the American College of Cardiology, Ameri›
can Heart Association,5 National Institute for Clinical
Excellence,6 and European Society of Cardiology7 have
all recommended using an implantable cardioverter
defibrillator as a primary prevention strategy in such
high risk patients. In addition, NICE recommends that
screening programmes should be put in place so that
these patients can be identified.
Screening requires assessment of ventricular
function, 24 hour ambulatory monitoring in those with
an ejection fraction of less than 35%, and an
electrophysiological study in those with non›sustained
ventricular tachycardia aimed at provoking sustained
ventricular tachycardia. Despite the recommendation
in September 2000 that screening programmes be put
in place, there seems to be none in the United
Kingdom. Screening should be undertaken as a
cascade as identification requires all three criteria.
Assessment of ventricular function is already required
by the national service framework for heart disease, for
which extra resource should be available, but only a
minority of post›infarction patients undergo ambula›
tory monitoring and extremely few undergo electro›
physiological studies.
Best guesses suggest that after an infarction about
1% of patients will fulfil all three criteria and therefore
be considered for cardioverter defibrillator
implantation.8–11 These estimates are based on a variety
of assumptions—that 4%›16% of post›infarction
patients will have an ejection fraction of 35% or
less,8 10 11 of these 12%›16% will have non›sustained
ventricular tachycardia on ambulatory monitoring,8 10
and that sustained ventricular tachycardia will be
inducible at electrophysiological study in 22%›35% of
these.11 12 There are 300 000 myocardial infarctions
each year in the United Kingdom; over half the
patients survive. Using these assumptions, over 1500
patients each year should be considered for an
implantable cardioverter defibrillator as a primary pre›
vention strategy. If the recommendations made by
NICE are adopted many patients should be screened
after infarction. About 24 000 should undergo
ambulatory monitoring; 16%, or about 4000, should
undergo electrophysiological study, and 1%, or about
250, should have a cardioverter defibrillator implanted.
Since the guidance from NICE was published, a
further primary prevention trial (MADIT 2) has shown
a relative reduction in mortality of 31% in post›
infarction patients treated with an implantable cardio›
verter defibrillator compared with the control group
receiving usual treatment.13 This trial used a much sim›
plified selection criterion—ejection fraction less than
30% after myocardial infarction—obviating the need
for the screening cascade described by NICE. It does
suggest, however, that at least five times as many
patients as fulfil the current NICE criteria might benefit
from an implanted defibrillator.
Increasing the number of patients being
investigated and treated according to the guidance
from NICE will need much additional resource. Till
then few British patients will receive the care
recommended by NICE and widely available in the
Western world.
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Bisphosphonates as adjuvant treatment for breast
cancer
Their effects are unclear, and long term trials are needed
Bisphosphonates are potent inhibitors of theosteoclastic bone resorption that is associatedwith skeletal metastases, with proved efficacy in
reducing skeletal complications in metastatic cancer.
Randomised clinical trials investigating the adjuvant
use of bisphosphonates to prevent bone metastases in
patients with breast cancer have yielded intriguing yet
conflicting results. Defining the potential role of these
agents in the treatment of breast cancer is of great
clinical relevance.
The skeleton is the first site of recurrence in
25›40% of patients with metastatic breast cancer. The
development of bone metastases entails complex
interactions between cancer cells and the microenvi›
ronment of bones. In the early establishment of metas›
tases, bone is destroyed by the osteoclast, which is
activated by a variety of cytokines produced directly or
indirectly by the tumour cell. As bone matrix is broken
down, a rich supply of mitogenic factors is released,
which in turn can lead to increased proliferation of
cancer cells.
Bisphosphonates are effective in treating conditions
in which excessive bone resorption and osteoclast activ›
ity prevail, including osteoporosis and Paget’s disease of
bone. Several randomised clinical trials in patients with
breast cancer with bone metastases have shown the abil›
ity of bisphosphonates to reduce skeletal related events
and symptoms, including pathological fractures, surgery,
radiation, compression of the spinal cord, hypercalcae›
mia, and pain, although they have not shown improved
survival.1–6 Clodronate and pamidronate have been
evaluated extensively in patients with metastatic cancer
and are widely used in oncology.1–3 Zoledronic acid and
ibandronic acid represent highly potent, newer genera›
tion bisphosphonates with recently shown benefit in
reducing skeletal related events.4–6
Preclinical studies show that bisphosphonates
might also be capable of preventing the development
of bone metastases. Laboratory data show that
bisphosphonates can inhibit adherence of breast
cancer cells to the bone matrix, inhibit release of
growth factors stored in the bone matrix, and enhance
the sensitivity of osteoclasts, macrophages, and tumour
cells to apoptosis.
Three randomised clinical trials of the oral
bisphosphonate clodronate as adjuvant treatment in
breast cancer have yielded conflicting results. A
German trial of 302 patients with primary breast can›
cer with immunocytochemical evidence of cancer cells
in a bone marrow aspirate randomised patients to two
years of clodronate or control. At almost five years of
follow up, a reduction in the recurrence of bone metas›
tases, a trend towards reduction in visceral metastases,
and an increase in overall survival were seen in the
clodronate group.7 8 The effect of clodronate as an
adjuvant seemed weakened with longer follow up.
A Finnish trial including 299 women with lymph
node positive breast cancer randomised to three years
of clodronate as an adjuvant showed virtually the
opposite result, with no effect on the rate of bone
metastasis and a deleterious effect on relapse rates of
non›bone metastasis as well as survival.9 After five years
of follow up, bone metastases were detected equally in
the clodronate and placebo groups, and non›skeletal
metastases were significantly more common in the
clodronate group. Overall survival was significantly
worse in the clodronate group.
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